Evidence map›Paper›PMID 37957464›Full record

ReviewDiabetes therapy : research, treatment and education of diabetes and related disorders2024

Cost-Effectiveness of Pharmacist Care in Diabetes Management: A Systematic Review.

Jiejin Zhu, Ying Zhou, Gang Wang

Open access · goldAbstract readReview
In one paragraph

Review in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Pilot of interactive texting for diabetes self-management education and support.Journal of the American Pharmacists Association : JAPhA
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jiejin ZhuDepartment of Clinical Pharmacy, Hangzhou First People's Hospital, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.ORCID https://orcid.org/0000-0002-8836-5711
Ying ZhouDepartment of Clinical Pharmacy, Hangzhou First People's Hospital, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China.ORCID https://orcid.org/0000-0002-0295-8736
Gang WangDepartment of Clinical Pharmacy, Hangzhou First People's Hospital, No. 261 Huansha Road, Hangzhou, 310006, Zhejiang, China. 88485534@163.com.ORCID http://orcid.org/0009-0000-0228-1326
Hangzhou First People's Hospital · CN

Funding

Hangzhou special project for Biomedicine and Health industry Development of Science and Technology 2023WJC061
6 · The paper itself

Abstract

introductionIn recent years, the role of pharmacists has undergone significant transformation to become more patient-centered and involved in managing chronic diseases. Nonetheless, it remains unclear whether pharmacist involvement in diabetes management is cost-effective. This study aimed to systematically review the cost-effectiveness and reporting quality in comprehensive economic evaluations of pharmacist management compared to standard care in diabetes.

methodsEligible studies included cost-effectiveness analyses employing pharmacist professional services as the intervention for diabetes. A literature search was conducted in the bibliographic databases Pubmed, Scopus, China National Knowledge Infrastructure (CNKI), and the International Health Technology Assessment (HTA) database from their inception until July 2023. Two independent reviewers performed title, abstract, full-text screening, and data abstraction and assessed the quality of reporting and methodological approaches using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS 2022) checklists.

resultsTwelve studies were identified with an average research quality score of 19.8, including cost-utility (n = 5) and cost-effectiveness (n = 7) analyses, with only four studies rated as high quality. The efficacy data were derived from randomized controlled trials (n = 7), retrospective studies (n = 2), and published literature sources (n = 2). Half of the included studies were conducted in high-income countries, while the other half was in upper-middle and lower-middle-income countries, respectively. Despite significant variations in the cost of pharmacist intervention, consistent findings demonstrate that pharmacist involvement in diabetes management is more cost-effective or even cost-saving than standard care, primarily attributed to better glycemic control, enhanced patient compliance, and reduced risks of medication-related problems.

conclusionThis systematic review substantiates that pharmacist involvement in diabetes management is cost-effective compared with standard care. However, the overall quality of reporting needs to be improved, and high-quality evidence is urgently needed to support healthcare decision-making in pharmacy practice.

Indexed as

Cost-effectivenessCost-utilityDiabetesDiabetes managementPharmaceutical carePharmacist

Identifiers

PMID37957464
PMCPMC10786784
OpenAlexW4388646899

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.